News

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...
US FDA approves Gilead's twice-yearly injection for HIV prevention
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
Long-acting HIV prevention drug from Gilead wins FDA approval. Will it get to the people who need it?
The drug is groundbreaking, potentially eliminating the need for a long-sought-after HIV vaccine. In her own words: Anne ...
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.
The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...
FDA Approves ‘Breakthough’ Drug to Prevent HIV
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag
Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
The FDA Just Approved a Long-Lasting Injection to Prevent HIV
Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...
FDA approves first twice-yearly injection that prevents HIV infection
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.
BioPharma Dive3d
FDA approves twice-yearly shot of Gilead drug for HIV prevention
The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...
BioSpace2d
Gilead Wins Historic Approval for Twice-Yearly HIV Drug
“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.
STAT3d
HIV protection with just two shots a year: FDA approves Gilead drug
A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...